| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 2.1K | 4.7% | 2.9% |
| Total Income | 2.2K | 3.5% | 1.5% |
| Expenditure | 2.2K | 3.5% | 3.7% |
| PBT | -104.12 | 70.8% | 309.3% |
| Net Profit | -136.19 | 37.3% | 3800.8% |
| OPM | 7.23% | 0.53pp | 19.14pp |
| NPM | -6.24% | 1.54pp | 5.64pp |
| EPS | 1.03 | 37.3% | 3333.3% |
Piramal Pharma Limited Announces Q3 and 9M FY26 Results with Revenue from Operations at ₹ 2,140 Crores and ₹ 6,117 Crores respectively
29 Jan 2026 · 29 Jan, 5:32 am
Summary
Piramal Pharma Limited, a leading global pharmaceutical, health and wellness company, announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31° December 2025. The company's revenue from operations for Q3FY26 was ₹ 2,140 Crores and for 9MFY26 was ₹ 6,117 Crores. The company's CDMO, CHG, and PCH businesses have shown mixed results with growth, regulatory delays, and inventory destocking impacting the revenue and profitability.
Key Highlights
- 1
Revenue growth in Q3/9M FY26 was impacted by inventory destocking and slower early-stage order inflows in H1FY26 in the CDMO business.
- 2
EBITDA Margin was impacted due to lower revenues but was partly offset by cost optimization and operational excellence efforts.
- 3
Seeing significant pick-up in RFPs with early signs of recovery in order inflows since October 2025 on the back of improved biopharma funding and increased M&A activities in the US.
Management Comments
Nandini Piramal
Chairperson, Piramal Pharma Limited
FY26 has been a muted year for the Company due to impact of inventory destocking and slower early-stage order inflows in H1FY26 in our CDMO business. However, in recent time, we are seeing early signs of recovery with pick-up in RFPs and order inflows on the back of improved biopharma funding and increased M&A activities in the US healthcare space. In our CHG business, we are investing in new products and expanding our presence in the ex-US markets. Acquiring niche brand like Kenalog, which is synergetic to our current business, is an important step in this direction. Our consumer business continues to outperform in its representative markets with robust growth in our power brands. Despite the slower growth in FY26, we continue to believe in long term growth prospects of our businesses and back them with timely investments in capacities and capabilities. Q4 has been historically the strongest quarter for the Company, and we expect this trend to continue this year as well.
Informational and educational content only. Not investment advice.